EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Relatlimab: a novel drug targeting immune checkpoint LAG-3 in melanoma therapy

Jingjing Su, Yiting Fu, Zitong Cui, Zain Abidin, Jingsong Yuan, Xinmiao Zhang, Runmin Li, Chunzhen Zhao

Frontiers in Pharmacology · 10.01.2024 · 14

DOI: 10.3389/fphar.2023.1349081 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 10.01.2024. Verfasst von Jingjing Su und 7 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Molecular Pharmacology and Translational Medicine and Department of Pharmacology, College of Pharmacy, Weifang Medical University, …. Die Arbeit wurde bisher 61-mal zitiert (Crossref) und nennt 112 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Relatlimab is a type of human immunoglobulin G4 monoclonal blocking antibody. It is the world’s first Lymphocyte-Activation Gene-3 (LAG-3) inhibitor and the third immune checkpoint inhibitor with clinical application, following PD-1 and CTLA-4. Relatlimab can bind to the LAG-3 receptor which blocks the interaction between LAG-3 and its ligand to reduce LAG-3 pathway-mediated immunosuppression and promote T-cell proliferation, inducing tumor cell death. On 18 March 2022, the U.S. FDA approved the fixed-dose combination of relatlimab developed by Bristol Myers Squibb with nivolumab, under the brand name Opdualag for the treatment of unresectable or metastatic melanoma in adult and pediatric patients aged 12 and older. This study comprehensively describes the mechanism of action and clinical trials of relatlimab and a brief overview of immune checkpoint drugs currently used for the treatment of melanoma.

Schlagwörter

Stichwörter der Autor:innen

LAG-3 inhibitorimmune checkpointmetastatic melanomanivolumabrelatlimab

Autor:innen und Institutionen

  • Key Laboratory of Molecular Pharmacology and Translational Medicine and Department of Pharmacology, College of Pharmacy, Weifang Medical University, Weifang, China.
  • Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, NY, United States.

Zitieren

APA

Su, J., Fu, Y., Cui, Z., Abidin, Z., Yuan, J., Zhang, X., Li, R., & Zhao, C. (2024). Relatlimab: a novel drug targeting immune checkpoint LAG-3 in melanoma therapy. Frontiers in Pharmacology, 14. https://doi.org/10.3389/fphar.2023.1349081

Vancouver

Su J, Fu Y, Cui Z, Abidin Z, Yuan J, Zhang X, et al. Relatlimab: a novel drug targeting immune checkpoint LAG-3 in melanoma therapy. Frontiers in Pharmacology. 2024;14. doi:10.3389/fphar.2023.1349081

BibTeX
@article{Su2024,
  author = {Su, Jingjing and Fu, Yiting and Cui, Zitong and Abidin, Zain and Yuan, Jingsong and Zhang, Xinmiao and Li, Runmin and Zhao, Chunzhen},
  title = {Relatlimab: a novel drug targeting immune checkpoint LAG-3 in melanoma therapy},
  journal = {Frontiers in Pharmacology},
  year = {2024},
  volume = {14},
  doi = {10.3389/fphar.2023.1349081}
}
Kostenlos starten →